Agios Pharma


Canaccord Pounds The Table On Agios Pharmaceuticals Following Fourth Quarter Update

Canaccord Genuity analyst John Newman was out pounding the table on Agios Pharmaceuticals (NASDAQ:AGIO) Tuesday, reiterating a Buy rating and a price target of …

Canaccord Raises Agios Pharma Price Target As Celgene Exercised Option To License AG-120

In a research report sent to investors today, Canaccord Genuity analyst John Newman maintained a Buy rating on Agios Pharma (NASDAQ:AGIO) and raised his …

Agios’ Current Valuation Reflects Many Of The Anticipated Positives, Says Roth Capital

In a research report released Monday, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral rating and a price …